Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.50 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

36 37 Next >

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

April 20, 2026

From BioMedWire

Via GlobeNewswire

Sarepta Therapeutics (NASDAQ:SRPT) Posts Q4 Revenue Beat Amid Deep Losses and Major Charges ↗

February 25, 2026

Via Chartmill

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug...

Via MarketMinute

Topics Intellectual Property Lawsuit

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 31, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500...

Via MarketMinute

Topics Economy Intellectual Property Stocks

Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics

March 26, 2026

CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular...

Via MarketMinute

Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data

March 26, 2026

CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years....

Via MarketMinute

The RNA Renaissance: Decoding Sarepta Therapeutics’ 34% Surge and the Future of Precision Medicine

March 26, 2026

On March 25, 2026, the biotechnology sector witnessed a tectonic shift as Sarepta Therapeutics (NASDAQ: SRPT) saw its share price skyrocket by 34% in a single trading session. This dramatic surge—the...

Via Finterra

Topics Retirement

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

March 25, 2026

Via Chartmill

Wednesday's session: top gainers and losers ↗

March 25, 2026

Via Chartmill

Which stocks are gapping on Wednesday? ↗

March 25, 2026

Via Chartmill

Sarepta Therapeutics (SRPT) at a Crossroads: A 2026 Deep Dive into the Future of Genetic Medicine

March 25, 2026

As of March 25, 2026, Sarepta Therapeutics (NASDAQ: SRPT) stands at a pivotal, albeit bruising, crossroads in the history of genetic medicine. Once the darling of the biotechnology sector for its...

Via Finterra

Topics Economy Intellectual Property Retirement

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

March 25, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

March 24, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

2 Beaten-Down Stocks That Still Aren't Worth Buying ↗

March 21, 2026

These stocks aren't nearly as cheap as they look.

Via The Motley Fool

Topics Cannabis

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

March 19, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study ↗

March 16, 2026

Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy.

Via Stocktwits

Topics Death

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

March 16, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

February 27, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

February 26, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today ↗

February 26, 2026

Data from Stocktwits showed that retail sentiment on SPY and QQQ diverged.

Via Stocktwits

Topics Artificial Intelligence ETFs Stocks

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat ↗

February 25, 2026

A new Cohort 8 study aims to reopen the non-walking patient market with data expected by the end of 2026.

Via Stocktwits

Topics Earnings

Sarepta (SRPT) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Sarepta (SRPT) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

February 25, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

February 24, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling ↗

February 24, 2026

Institutional support remains strong in February, with 134 investors increasing positions and 61 initiating new stakes.

Via Stocktwits

Topics Intellectual Property

Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy ↗

February 20, 2026

While Sarepta’s gene therapy for the treatment of DMD called Elevidys was approved by the FDA in 2023, Regenxbio is developing its treatment.

Via Stocktwits

Topics Intellectual Property Lawsuit

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

February 11, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

February 04, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.